Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

PLIAGLIS Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Pliaglis, and what generic alternatives are available?

Pliaglis is a drug marketed by Taro Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has seventeen patent family members in eleven countries.

The generic ingredient in PLIAGLIS is lidocaine; tetracaine. There are twenty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lidocaine; tetracaine profile page.

US ANDA Litigation and Generic Entry Outlook for Pliaglis

Pliaglis was eligible for patent challenges on December 31st, 1968.

Summary for PLIAGLIS
Drug patent expirations by year for PLIAGLIS
Drug Prices for PLIAGLIS

See drug prices for PLIAGLIS

Recent Clinical Trials for PLIAGLIS

Identify potential brand extensions & 505(b)(2) entrants

American Association of EndodontistsPhase 4
University of MichiganPhase 4
Galderma Laboratories, L.P.Phase 4

See all PLIAGLIS clinical trials

Pharmacology for PLIAGLIS

US Patents and Regulatory Information for PLIAGLIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharms PLIAGLIS lidocaine; tetracaine CREAM;TOPICAL 021717-001 Jun 29, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.